Developer docs
API playgroundTry for free, no card

Search company profiles

PolyPid

Full company profile

uuid0002cak

Namestring
PolyPid
Legal namestring
PolyPid Ltd.
Websiteurl
polypid.com
Company typeenum
Public
Founded yearint
2008
Descriptiontext

PolyPid Ltd. is an Israeli clinical-stage biopharmaceutical company founded in 2008 and listed on Nasdaq (PYPD) since June 26, 2020, headquartered in Petach Tikva, Israel with a U.S. subsidiary in Summit, NJ. The company develops long-acting, controlled-release medicines built on its proprietary Kynatrix™ technology (and the underlying PLEX, Polymer-Lipid Encapsulation matriX platform), which enables customizable, localized, linear drug delivery over periods ranging from days to weeks without burst effects, allowing high local concentration with negligible systemic exposure.

PolyPid's lead product candidate, D-PLEX100, is a first-in-class incisional prophylactic therapy that delivers sustained, localized doxycycline directly at the surgical incision for up to 30 days to prevent surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery. The Phase 3 SHIELD II trial demonstrated a 60% relative risk reduction in SSI incidence (p=0.0013) and a 64% reduction in clinically significant wound infections per ASEPSIS scoring (p=0.0103). The product received FDA Breakthrough Therapy Designation, and the NDA was accepted with Priority Review, setting a PDUFA goal date of November 28, 2026. The pipeline extends the platform into oncology (OncoPLEX) and orthopedic infections (BonyPid, D-PLEX500), with the February 2026 Kynatrix launch positioning the company toward metabolic and adjacent therapeutic areas.

PolyPid's revenue model is currently pre-commercialization with $0 reported revenue across 2022–2025 and net losses of $34.2M in 2025 and $7.7M in Q1 2026. In July 2026, the company entered an exclusive U.S./Canada commercialization partnership with Azurity Pharmaceuticals valued at over $320 million, comprising $15M upfront, $15M upon FDA NDA acceptance, tiered royalties in the mid-teen to mid-twenties percent range, and up to approximately $300M in additional regulatory, development, and sales-based milestones; Azurity will commercialize the product while PolyPid manufactures and supplies it. Target customers are hospitals and surgical centers performing colorectal surgery, reached through Azurity's hospital-focused sales force, with U.S. commercial launch targeted for Q1 2027.

Short descriptiontext

PolyPid is an Israeli clinical-stage biopharmaceutical company developing long-acting, localized drug delivery products using its proprietary Kynatrix/PLEX platform. Its lead candidate, D-PLEX100, delivers 30-day localized doxycycline to prevent surgical site infections in colorectal surgery, partnered with Azurity for U.S./Canada commercialization.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersPetah Tiqva, Israel
HQ citystring
Petah Tiqva
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
extended drug delivery, surgical site infections, controlled-release pharmaceuticals, localized antibiotic therapy, biopharmaceutical drug development
NAICS code4 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
  • Scientific Research and Development Services5417
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Commercial Physical & Biological Research8731
Product category
Specialty Pharmaceuticals — Sustained-Release Drug Delivery
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Product Sales through Azurity Partnership
TypeLicensing Royalties
Description

Upon FDA approval and commercialization, PolyPid will manufacture and supply D-PLEX100 to Azurity for a transfer price and receive tiered royalties ranging from mid-teen to mid-twenties percentages on future sales in U.S. and Canada.

globenewswire.com
2Milestone Payments from Azurity
TypeLicensing Royalties
Description

PolyPid will receive $15 million upon signing the agreement (July 2026) and an additional $15 million upon FDA acceptance of the NDA. Additional regulatory, development, and sales-based milestone payments up to approximately $300 million.

globenewswire.com
3Warrant Exercises
TypeLicensing Royalties
Description

PolyPid secured $26.7 million through warrant exercises following successful Phase 3 SHIELD II trial results, extending operational runway beyond FDA approval.

globenewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

PolyPid develops long-acting, controlled-release pharmaceutical products based on its proprietary Kynatrix (PLEX) technology, which enables customizable, localized, burst-free drug delivery over periods ranging from days to weeks. Its lead commercial-stage product, D-PLEX100, delivers sustained doxycycline release directly at the surgical incision for 30 days to prevent surgical site infections (SSIs) in abdominal colorectal surgery patients. Additional pipeline candidates extend the platform into oncology (OncoPLEX) and orthopedic (BonyPid, D-PLEX500) indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 60% relative risk reduction in SSI incidence (p=0.0013)
+3 more records
Product overview1 text field

PolyPid is an innovative biopharmaceutical company developing long-acting, controlled-release drugs using its proprietary PLEX and Kynatrix technology platforms. The company's lead product D-PLEX100 is a first-in-class incisional prophylactic therapy for preventing surgical site infections, delivering sustained localized antibiotic exposure directly at surgical incisions for 30 days. The pipeline spans surgical care (D-PLEX100), oncology (OncoPLEX), and orthopedic applications (BonyPid, D-PLEX500). In July 2026, PolyPid entered an exclusive $320M+ commercialization partnership with Azurity Pharmaceuticals for D-PLEX100 in the U.S. and Canada, with FDA NDA acceptance and Priority Review granted, targeting commercial launch in Q1 2027.

Product and service6 records
1D-PLEX100
CategorySpecialty Pharmaceutical — Surgical Infection Prophylaxis
Description

First-in-class incisional prophylactic therapy that uses the Kynatrix technology to deliver sustained, localized doxycycline release at the surgical incision for 30 days, designed to prevent surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery. Demonstrated a 60% relative risk reduction in SSI incidence in the Phase 3 SHIELD II trial.

2Kynatrix Platform
CategoryDrug Delivery Technology Platform
Description

Next-generation drug delivery technology platform enabling customizable, localized, extended drug delivery over periods ranging from days to weeks without burst effects, ensuring linear, high-concentration exposure across a broad range of therapeutic agents.

3PLEX Technology
CategoryDrug Delivery Technology Platform
Description

Proprietary Polymer-Lipid Encapsulation matriX technology enabling controlled local delivery of drugs at predetermined release rates and durations over periods ranging from days to several months, designed to address shortcomings of systemic administration and existing localized delivery systems.

4OncoPLEX
CategoryPipeline Product — Oncology
Description

Pipeline product candidate applying the PLEX platform to deliver sustained docetaxel release, intended to overcome therapeutic barriers in post-resection solid tumors and glioblastoma.

5BonyPid
CategoryPipeline Product — Orthopedic Infection Prevention
Description

Pipeline orthopedic product candidate using a polymer-lipid coating for antibiotic delivery to treat and prevent infections in bones, including osteomyelitis and Gustilo III infected open fractures.

6D-PLEX500
CategoryPipeline Product — Dental/Implant Infection
Description

Pipeline product candidate for peri-implantitis treatment using a local, biodegradable, prolonged-release doxycycline-formulated bone graft.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-07-21
Description

PolyPid entered an exclusive commercial partnership with Azurity Pharmaceuticals for D-PLEX100 in the U.S. and Canada. PolyPid will receive $15M upfront, $15M upon FDA NDA acceptance, and up to ~$300M in additional milestones, plus tiered royalties (mid-teen to mid-twenties percentages). Azurity will commercialize the product while PolyPid manufactures and supplies it. Azurity will also fund clinical development for potential label expansion beyond abdominal surgery SSI indications.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Stryker's surgical and infection-prevention segments provide a wide array of surgical devices and hospital consumables. While Stryker does not have a direct D-PLEX100 equivalent, it competes for hospital SSI-prevention budgets and formulary space via adjacent product categories.

TypeEmerging player
Description

Iterum develops oral and IV antibiotics (sulopenem) targeting resistant infections treated in hospital and community settings. Comparable to PolyPid as an emerging anti-infective player with a focus on reducing surgical and hospital-acquired infections, though its delivery modality is conventional rather than localized sustained-release.

TypeDirect peer
Description

Eagle Pharmaceuticals develops improved formulations and sustained-release injectables (e.g., vasopressin, PEMFEXY) that compete on pharmacokinetic and dosing advantages over standard hospital drugs. Eagle is a comparable specialty pharma whose value proposition is reformulating existing molecules for hospital use via proprietary delivery technology.

TypeEmerging player
Description

Citius is a clinical-stage specialty pharma developing oncology and anti-infective products including Mino-Lok (a catheter-lock solution for catheter-related bloodstream infections). Comparable to PolyPid as an emerging player in hospital-administered anti-infective therapies addressing high-acuity infection indications.

TypeBroad incumbent
Description

Johnson & Johnson's MedTech division, including Ethicon and DePuy Synthes, holds dominant positions in surgical wound closure, orthopedics, and infection prevention. J&J is a broad incumbent whose hospital channel and SSI-adjacent product lines compete for the same surgeon mindshare as D-PLEX100.

TypeBroad incumbent
Description

Medtronic's Surgical Solutions division offers a broad portfolio of surgical instruments, hemostats, and infection-related products used in operating rooms globally. As a broad incumbent with scale hospital sales coverage, Medtronic is the primary existing-relationship competitor PolyPid must displace for surgical SSI adoption.

TypeDirect peer
Description

Pacira commercializes EXPAREL, a long-acting injectable local anesthetic using a multivesicular liposomal platform for sustained drug release. Pacira is the closest public-market peer to PolyPid: a specialty biopharma whose value is anchored by a single sustained-release technology deployed in surgical care settings.

TypeBroad incumbent
Description

BD's Surgery business (previously led by new PolyPid Chairman Brooke Story) is the dominant provider of surgical infection prevention products, skin antiseptics, and surgical devices in U.S. hospitals. BD is a broad incumbent that competes with D-PLEX100 through established SSI-prevention product portfolios and deep hospital relationships.

TypeDirect peer
Description

Heron develops sustained-release polymer-based drug delivery products (ZYNRELEF, APONVIE, CINVANTI) using a bioerodible polymer platform that targets the surgical and postoperative care setting. The shared thesis - proprietary extended-release technology deployed in hospitals to displace standard of care - is directly analogous to PolyPid's D-PLEX100/Kynatrix.

TypeDirect peer
Description

DURECT is a clinical-stage specialty pharma built around its DUR-928 and SABER/SUCROVEST sustained-release drug delivery platforms, with applications in acute organ injury and postoperative pain. Comparable to PolyPid as a small-cap, technology-platform-driven biopharma targeting localized or controlled-release drug delivery for medical indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PolyPid

Specialty Pharmaceuticals — Sustained-Release Drug Deliverypolypid.com

PolyPid is an Israeli clinical-stage biopharmaceutical company developing long-acting, localized drug delivery products using its proprietary Kynatrix/PLEX platform. Its lead candidate, D-PLEX100, delivers 30-day localized doxycycline to prevent surgical site infections in colorectal surgery, partnered with Azurity for U.S./Canada commercialization.

What PolyPid does

PolyPid Ltd. is an Israeli clinical-stage biopharmaceutical company founded in 2008 and listed on Nasdaq (PYPD) since June 26, 2020, headquartered in Petach Tikva, Israel with a U.S. subsidiary in Summit, NJ. The company develops long-acting, controlled-release medicines built on its proprietary Kynatrix™ technology (and the underlying PLEX, Polymer-Lipid Encapsulation matriX platform), which enables customizable, localized, linear drug delivery over periods ranging from days to weeks without burst effects, allowing high local concentration with negligible systemic exposure.

PolyPid's lead product candidate, D-PLEX100, is a first-in-class incisional prophylactic therapy that delivers sustained, localized doxycycline directly at the surgical incision for up to 30 days to prevent surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery. The Phase 3 SHIELD II trial demonstrated a 60% relative risk reduction in SSI incidence (p=0.0013) and a 64% reduction in clinically significant wound infections per ASEPSIS scoring (p=0.0103). The product received FDA Breakthrough Therapy Designation, and the NDA was accepted with Priority Review, setting a PDUFA goal date of November 28, 2026. The pipeline extends the platform into oncology (OncoPLEX) and orthopedic infections (BonyPid, D-PLEX500), with the February 2026 Kynatrix launch positioning the company toward metabolic and adjacent therapeutic areas.

PolyPid's revenue model is currently pre-commercialization with $0 reported revenue across 2022–2025 and net losses of $34.2M in 2025 and $7.7M in Q1 2026. In July 2026, the company entered an exclusive U.S./Canada commercialization partnership with Azurity Pharmaceuticals valued at over $320 million, comprising $15M upfront, $15M upon FDA NDA acceptance, tiered royalties in the mid-teen to mid-twenties percent range, and up to approximately $300M in additional regulatory, development, and sales-based milestones; Azurity will commercialize the product while PolyPid manufactures and supplies it. Target customers are hospitals and surgical centers performing colorectal surgery, reached through Azurity's hospital-focused sales force, with U.S. commercial launch targeted for Q1 2027.

PolyPid firmographics

Firmographics
Name
PolyPid
Legal name
PolyPid Ltd.
Website
https://polypid.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
51–100 employees
Short description
PolyPid is an Israeli clinical-stage biopharmaceutical company developing long-acting, localized drug delivery products using its proprietary Kynatrix/PLEX platform. Its lead candidate, D-PLEX100, delivers 30-day localized doxycycline to prevent surgical site infections in colorectal surgery, partnered with Azurity for U.S./Canada commercialization.
Ownership category
akta.pro rank

Where PolyPid is headquartered

Location

Headquarters

HQ city
Petah Tiqva
HQ country
Israel
HQ region
Middle East

Offices2 records

Markets served

PolyPid business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Product Sales through Azurity Partnership: Upon FDA approval and commercialization, PolyPid will manufacture and supply D-PLEX100 to Azurity for a transfer price and receive tiered royalties ranging from mid-teen to mid-twenties percentages on future sales in U.S. and Canada.
  2. Milestone Payments from Azurity: PolyPid will receive $15 million upon signing the agreement (July 2026) and an additional $15 million upon FDA acceptance of the NDA. Additional regulatory, development, and sales-based milestone payments up to approximately $300 million.
  3. Warrant Exercises: PolyPid secured $26.7 million through warrant exercises following successful Phase 3 SHIELD II trial results, extending operational runway beyond FDA approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

PolyPid product offering

Product offering

Core offering

PolyPid develops long-acting, controlled-release pharmaceutical products based on its proprietary Kynatrix (PLEX) technology, which enables customizable, localized, burst-free drug delivery over periods ranging from days to weeks. Its lead commercial-stage product, D-PLEX100, delivers sustained doxycycline release directly at the surgical incision for 30 days to prevent surgical site infections (SSIs) in abdominal colorectal surgery patients. Additional pipeline candidates extend the platform into oncology (OncoPLEX) and orthopedic (BonyPid, D-PLEX500) indications.

Product overview

PolyPid is an innovative biopharmaceutical company developing long-acting, controlled-release drugs using its proprietary PLEX and Kynatrix technology platforms. The company's lead product D-PLEX100 is a first-in-class incisional prophylactic therapy for preventing surgical site infections, delivering sustained localized antibiotic exposure directly at surgical incisions for 30 days. The pipeline spans surgical care (D-PLEX100), oncology (OncoPLEX), and orthopedic applications (BonyPid, D-PLEX500). In July 2026, PolyPid entered an exclusive $320M+ commercialization partnership with Azurity Pharmaceuticals for D-PLEX100 in the U.S. and Canada, with FDA NDA acceptance and Priority Review granted, targeting commercial launch in Q1 2027.

Differentiator

Problem solved

Functional benefit

Products and services

  • D-PLEX100 First-in-class incisional prophylactic therapy that uses the Kynatrix technology to deliver sustained, localized doxycycline release at the surgical incision for 30 days, designed to prevent surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery. Demonstrated a 60% relative risk reduction in SSI incidence in the Phase 3 SHIELD II trial.
  • Kynatrix Platform Next-generation drug delivery technology platform enabling customizable, localized, extended drug delivery over periods ranging from days to weeks without burst effects, ensuring linear, high-concentration exposure across a broad range of therapeutic agents.
  • PLEX Technology Proprietary Polymer-Lipid Encapsulation matriX technology enabling controlled local delivery of drugs at predetermined release rates and durations over periods ranging from days to several months, designed to address shortcomings of systemic administration and existing localized delivery systems.
  • OncoPLEX Pipeline product candidate applying the PLEX platform to deliver sustained docetaxel release, intended to overcome therapeutic barriers in post-resection solid tumors and glioblastoma.
  • BonyPid Pipeline orthopedic product candidate using a polymer-lipid coating for antibiotic delivery to treat and prevent infections in bones, including osteomyelitis and Gustilo III infected open fractures.
  • D-PLEX500 Pipeline product candidate for peri-implantitis treatment using a local, biodegradable, prolonged-release doxycycline-formulated bone graft.

Quantifiable outcome

  • 60% relative risk reduction in SSI incidence (p=0.0013)
  • +3 more outcomes

Companies that use PolyPid

Customer profile

Segments2 records

Ideal customer profiles1 record

PolyPid technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

PolyPid partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Azurity PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 21 July 2026PolyPid entered an exclusive commercial partnership with Azurity Pharmaceuticals for D-PLEX100 in the U.S. and Canada. PolyPid will receive $15M upfront, $15M upon FDA NDA acceptance, and up to ~$300M in additional milestones, plus tiered royalties (mid-teen to mid-twenties percentages). Azurity will commercialize the product while PolyPid manufactures and supplies it. Azurity will also fund clinical development for potential label expansion beyond abdominal surgery SSI indications.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

PolyPid competitors and assessment

Company assessment

Broad incumbents

  • Stryker Corporation: Stryker's surgical and infection-prevention segments provide a wide array of surgical devices and hospital consumables. While Stryker does not have a direct D-PLEX100 equivalent, it competes for hospital SSI-prevention budgets and formulary space via adjacent product categories.
  • Johnson & Johnson (J&J MedTech): Johnson & Johnson's MedTech division, including Ethicon and DePuy Synthes, holds dominant positions in surgical wound closure, orthopedics, and infection prevention. J&J is a broad incumbent whose hospital channel and SSI-adjacent product lines compete for the same surgeon mindshare as D-PLEX100.
  • Medtronic: Medtronic's Surgical Solutions division offers a broad portfolio of surgical instruments, hemostats, and infection-related products used in operating rooms globally. As a broad incumbent with scale hospital sales coverage, Medtronic is the primary existing-relationship competitor PolyPid must displace for surgical SSI adoption.
  • Becton Dickinson (BD): BD's Surgery business (previously led by new PolyPid Chairman Brooke Story) is the dominant provider of surgical infection prevention products, skin antiseptics, and surgical devices in U.S. hospitals. BD is a broad incumbent that competes with D-PLEX100 through established SSI-prevention product portfolios and deep hospital relationships.

Emerging players

  • Iterum Therapeutics: Iterum develops oral and IV antibiotics (sulopenem) targeting resistant infections treated in hospital and community settings. Comparable to PolyPid as an emerging anti-infective player with a focus on reducing surgical and hospital-acquired infections, though its delivery modality is conventional rather than localized sustained-release.
  • Citius Pharmaceuticals: Citius is a clinical-stage specialty pharma developing oncology and anti-infective products including Mino-Lok (a catheter-lock solution for catheter-related bloodstream infections). Comparable to PolyPid as an emerging player in hospital-administered anti-infective therapies addressing high-acuity infection indications.

Direct peers

  • Eagle Pharmaceuticals: Eagle Pharmaceuticals develops improved formulations and sustained-release injectables (e.g., vasopressin, PEMFEXY) that compete on pharmacokinetic and dosing advantages over standard hospital drugs. Eagle is a comparable specialty pharma whose value proposition is reformulating existing molecules for hospital use via proprietary delivery technology.
  • Pacira BioSciences: Pacira commercializes EXPAREL, a long-acting injectable local anesthetic using a multivesicular liposomal platform for sustained drug release. Pacira is the closest public-market peer to PolyPid: a specialty biopharma whose value is anchored by a single sustained-release technology deployed in surgical care settings.
  • Heron Therapeutics: Heron develops sustained-release polymer-based drug delivery products (ZYNRELEF, APONVIE, CINVANTI) using a bioerodible polymer platform that targets the surgical and postoperative care setting. The shared thesis - proprietary extended-release technology deployed in hospitals to displace standard of care - is directly analogous to PolyPid's D-PLEX100/Kynatrix.
  • DURECT Corporation: DURECT is a clinical-stage specialty pharma built around its DUR-928 and SABER/SUCROVEST sustained-release drug delivery platforms, with applications in acute organ injury and postoperative pain. Comparable to PolyPid as a small-cap, technology-platform-driven biopharma targeting localized or controlled-release drug delivery for medical indications.

Market position

Strengths5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

PolyPid social profiles

Digital presence

PolyPid compliance and trust

Trust signal

Compliance4 records

PolyPid financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PolyPid leadership team

Management profile

Number of profiles

Profiles8 records

PolyPid subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

PolyPid funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PolyPid M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PolyPid

What does PolyPid do?

PolyPid develops long-acting, controlled-release pharmaceutical products based on its proprietary Kynatrix (PLEX) technology, which enables customizable, localized, burst-free drug delivery over periods ranging from days to weeks. Its lead commercial-stage product, D-PLEX100, delivers sustained doxycycline release directly at the surgical incision for 30 days to prevent surgical site infections (SSIs) in abdominal colorectal surgery patients. Additional pipeline candidates extend the platform into oncology (OncoPLEX) and orthopedic (BonyPid, D-PLEX500) indications.

Is PolyPid a public or private company?

PolyPid is a public company. It is classified as public and is currently operating.

When was PolyPid founded?

PolyPid was founded in 2008. It employs 51 to 100 people.

Where is PolyPid based?

PolyPid is headquartered in Petah Tiqva, Israel, in the Middle East region.

How does PolyPid make money?

Three revenue lines are on record. Product Sales through Azurity Partnership is the primary driver. The others are milestone Payments from Azurity and warrant Exercises.

Who are PolyPid's main competitors?

Broad incumbents on record are Stryker Corporation, Johnson & Johnson (J&J MedTech), Medtronic and Becton Dickinson (BD). Emerging players are Iterum Therapeutics and Citius Pharmaceuticals. Direct peers are Eagle Pharmaceuticals, Pacira BioSciences, Heron Therapeutics and DURECT Corporation.

Does PolyPid have an API?

No public API is recorded for PolyPid.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsPolyPid (NASDAQ:PYPD) Rating Lowered to Hold at Wall Street ZenWall Street Zen downgraded PolyPid from Buy to Hold, while other analysts have mixed ratings. The company reported Q3 EPS of -$0.24, missing the $0.91 consensus, with revenue of $30 million. Analysts forecast a -0.44 EPS for the current year.TradingViewHC Wainwright & Co. maintains PolyPid at Buy, keeps price target at $13HC Wainwright & Co. maintained PolyPid at Buy and kept its price target at $13. The target implies a 97% upside from the Nov 11 close of $6.60. The rating is not investment advice.The Motley FoolPolyPid: 3 Key Takeaways for Long-Term InvestorsPolyPid's Q3 2026 earnings call reported progress toward the Nov. 28, 2026 PDUFA target for D-PLEX100, with Azurity's sales channels reaching over 1,700 U.S. hospitals. The company regained exclusive European rights and holds $15.5 million in cash, funding operations into 2028.The Motley FoolPolyPid (PYPD) Q3 2026 Earnings Call TranscriptPolyPid reported a Q3 2026 net loss of $5.8 million, down from $7.5 million in 2025, with cash of $15.5 million. The company's D-PLEX100 NDA is under priority review with a Nov. 28 PDUFA date, and it plans a U.S. launch in early 2027 with Azurity.BenzingaPolyPid Q3 2026 Earnings Call Transcript - PolyPid (NASDAQ:PYPD)PolyPid reported Q3 2026 net loss of $5.8 million, down from $7.5 million, with R&D expenses rising to $6.5 million. Its D-PLEX100 NDA is under FDA priority review with a PDUFA goal of November 28, 2026, and a $15 million milestone payment from Azurity is expected. The company expects cash to fund operations into 2028.Stock TitanPolyPid Q3 results: $30M received from AzurityPolyPid reported Q3 2026 net loss of $5.8 million and received $30 million in milestone payments from Azurity, with over $290 million in additional milestones available. The FDA's PDUFA goal date for D-PLEX₁₀₀ is November 28, 2026, with a potential U.S. launch in early 2027.The future of tradingPolyPid Ltd <pypd.oq> expected to post earnings of 6 cents a share - Earnings PreviewPolyPid Ltd is expected to report quarterly earnings of 6 cents per share and revenue of $18 million for the period ending September 30, 2026. The mean analyst estimate is unchanged, with a current average rating of 'buy' and a median 12-month price target of $12.00.Business & FinancialSurgical Site Infections Market And Pipeline Appear Robust With Key Pharma Companies Actively Working In The Therapeutics Segment DelveinsightDelveInsight released a report on the surgical site infections market, covering the 7MM and pipeline. PolyPid's D-PLEX100 showed a 60% reduction in incisional SSIs in its Phase III trial, with an FDA decision expected in Q1 2027. No SSI-specific products are approved in the US, Europe, or Japan.MarketBeatPolyPid Ltd. (NASDAQ:PYPD) Shares Shorted: Short Interest Up 78.6% in OctoberShort interest in PolyPid Ltd. rose 78.6% to 225,458 shares as of October 15th, representing 1.6% of shares sold short. The stock traded down $0.20 to $5.39, and analysts have a consensus target price of $11.00 with a Moderate Buy rating.American Banking and Market NewsPolyPid Ltd. (NASDAQ:PYPD) Stock Has Average Target Price of $11.00PolyPid Ltd. received a consensus 'Moderate Buy' rating from five analysts, with an average 1-year price target of $11.00. The stock opened at $5.39, and institutional investors hold 26.47% of shares. Analysts predict a current-year EPS of -$0.44.